The Bristol Myers Squibb-backed oncology drug developer ultimately raised nearly $144m in its initial public offering.
Ikena Oncology, a US-based cancer therapy developer backed by pharmaceutical firm Bristol Myers Squibb (BMS), has closed its initial public offering at almost $144m. The company had issued more than 7.81 million shares priced at $16.00 each last month, and they doubled in price to $32.00 by the end of their first day of trading.…
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.